MARKET

CLRB

CLRB

Cellectar Biosciences Inc
NASDAQ
3.080
-0.060
-1.91%
Opening 12:58 05/29 EDT
OPEN
2.980
PREV CLOSE
3.140
HIGH
3.155
LOW
2.950
VOLUME
155.45K
TURNOVER
--
52 WEEK HIGH
20.59
52 WEEK LOW
2.430
MARKET CAP
24.61M
P/E (TTM)
-0.4154
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLRB last week (0518-0522)?
Weekly Report · 4d ago
Cellectar Biosciences Bets on Iopofosine Breakthrough
TipRanks · 05/20 05:19
Cellectar Biosciences Files Prospectus For Offering Of Up To 51.2M Shares Of Common Stock By Selling Stockholders
Benzinga · 05/19 21:11
Cellectar Biosciences files to sell 51.21M shares of common stock for holders
TipRanks · 05/19 21:10
CELLECTAR BIOSCIENCES INC - FILES FOR OFFERING OF UP TO 51.2 MLN SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING
Reuters · 05/19 21:08
Cellectar Biosciences Announces Board Changes and New Director
TipRanks · 05/18 22:01
Cellectar BioSciences announces annual shareholder meeting notice
PUBT · 05/18 21:02
Cellectar Biosciences appoints Nantahala analyst Andrew Gu to board
PUBT · 05/18 20:17
More
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.